Exchange: NYSE·Updated 07:30 PM EDT

ZBH News

News
all
press releases
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
More News
Are Investors Undervaluing Baxter International (BAX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
Ambulatory Surgery Centers Are Becoming ISRG's New Growth Engine
Intuitive Surgical is expanding robotic surgery in ASCs with lower-cost XiR systems, opening access to new customers and outpatient procedures.
Zacks
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Why Is Zimmer (ZBH) Up 1.8% Since Last Earnings Report?
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
Is Zimmer Biomet Stock Worth Retaining in Your Portfolio Now?
ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.
Zacks
Is ISRG's Software Strategy Becoming as Important as Its Robots?
ISRG's software roadmap is strengthening da Vinci 5, with new features, renewals and recurring service revenues reinforcing its digital ecosystem.
Zacks
SYK Stock Gains 3.8% Since March-End: What's Driving the Uptrend?
Stryker has gained 3.8% since March-end as Mako robotics, hospital capital demand and international growth drive momentum.
Zacks
Is SYK Worth Buying as Growth Improves but Execution Risks Persist?
Stryker's stronger growth, margin gains and product pipeline support the case, but cyber costs, supply constraints and acquisition execution keep risks elevated.
Zacks

Advertisement|Remove ads.